This announcement is a separate document:
Actinogen Medical Ltd: First patient treated in ACW XanaMIA ph 2b Alzheimers trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.